Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats - PubMed (original) (raw)

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

D Edelstein et al. Diabetologia. 1992 Jan.

Abstract

We studied the effect of aminoguanidine, an inhibitor of advanced glycation product formation, on albuminuria in chronically diabetic spontaneously hypertensive rats. At the time of killing, there was no statistically significant difference in blood glucose concentration between the treated and untreated diabetic animals (18.2 +/- 0.69 mmol/l), nor was there any difference among the non-diabetic, diabetic untreated, and diabetic treated rats with respect to blood pressure (169 +/- 6.9 mm Hg). However, non-diabetic hypertensive animals had a mean quantitative 24-h urinary albumin excretion of 28 +/- 2 mg albumin/24-h, while untreated diabetic hypertensive animals averaged nearly four times that amount (106 +/- 3 mg albumin/24 h). Without affecting blood pressure, aminoguanidine treatment of diabetic hypertensive animals decreased the diabetic-associated elevation in urinary albumin excretion by 75% (48 +/- 2 mg/24 h). These data suggest than inhibition of advanced glycation product formation ameliorates the glomerular dysfunction caused by chronic hyperglycaemia.

PubMed Disclaimer

Similar articles

• Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat.
  Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Hammes HP, et al. Diabetologia. 1994 Jan;37(1):32-5. doi: 10.1007/BF00428774. Diabetologia. 1994. PMID: 8150227
• Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats.
  Huijberts MS, Wolffenbuttel BH, Crijns FR, Nieuwenhuijzen Kruseman AC, Bemelmans MH, Struijker Boudier HA. Huijberts MS, et al. Diabetologia. 1994 Jan;37(1):10-4. doi: 10.1007/BF00428771. Diabetologia. 1994. PMID: 8150221
• Renoprotective effects of a novel inhibitor of advanced glycation.
  Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME. Forbes JM, et al. Diabetologia. 2001 Jan;44(1):108-14. doi: 10.1007/s001250051587. Diabetologia. 2001. PMID: 11206401
• Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.
  Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, Allen TJ, Cooper ME. Davis BJ, et al. Diabetologia. 2004 Jan;47(1):89-97. doi: 10.1007/s00125-003-1256-8. Epub 2003 Nov 29. Diabetologia. 2004. PMID: 14647892
• Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.
  Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Soulis-Liparota T, et al. Diabetes. 1991 Oct;40(10):1328-34. doi: 10.2337/diab.40.10.1328. Diabetes. 1991. PMID: 1834497

Cited by

• Gold Nanoparticle-Bioconjugated Aminoguanidine Inhibits Glycation Reaction: An In Vivo Study in a Diabetic Animal Model.
  Ahmad S, Khan MS, Alouffi S, Khan S, Khan M, Akashah R, Faisal M, Shahab U. Ahmad S, et al. Biomed Res Int. 2021 May 12;2021:5591851. doi: 10.1155/2021/5591851. eCollection 2021. Biomed Res Int. 2021. PMID: 34055984 Free PMC article.
• Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies.
  Chen JH, Lin X, Bu C, Zhang X. Chen JH, et al. Nutr Metab (Lond). 2018 Oct 10;15:72. doi: 10.1186/s12986-018-0306-7. eCollection 2018. Nutr Metab (Lond). 2018. PMID: 30337945 Free PMC article. Review.
• Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.
  Lyons TJ, Jenkins AJ. Lyons TJ, et al. Diabetes Rev (Alex). 1997;5(4):365-391. Diabetes Rev (Alex). 1997. PMID: 26366051 Free PMC article.
• Pathophysiology of the diabetic kidney.
  Vallon V, Komers R. Vallon V, et al. Compr Physiol. 2011 Jul;1(3):1175-232. doi: 10.1002/cphy.c100049. Compr Physiol. 2011. PMID: 23733640 Free PMC article. Review.
• Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).
  Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Takeuchi M, Maeda S, Yamagishi S. Nakamura T, et al. Oxid Med Cell Longev. 2010 Sep-Oct;3(5):304-7. doi: 10.4161/oxim.3.5.13069. Epub 2010 Sep 1. Oxid Med Cell Longev. 2010. PMID: 21150335 Free PMC article.

References

1. 1. Metabolism. 1973 May;22(5):715-22 - PubMed
2. 1. Br Med J (Clin Res Ed). 1987 Jun 6;294(6585):1443-7 - PubMed
3. 1. Lab Invest. 1989 Apr;60(4):486-91 - PubMed
4. 1. Am J Physiol. 1990 Mar;258(3 Pt 2):H793-805 - PubMed
5. 1. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6107-11 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information